Press Release: PureHealth Reports Net Profit of USD 337 Million in H1 2026

Dow Jones
Jul 31
   -- Group revenue increased 9% year-on-year to USD 4.0 billion, driven by 
      growing contributions from international operations and resilient 
      performance across its insurance vertical 
 
   -- International operations contributed 33% of Group revenue 
 
   -- EBITDA increased 24% year-on-year to USD 782 million driven by growing 
      contributions from higher-margin international operations 
 
   -- Net Profit increased 20% year on year to USD 337 Million 
 
   -- Patient activity across the UAE network strengthened, with hospital bed 
      occupancy reaching 75% in H1 2026 

ABU DHABI, UAE, July 31, 2026 /PRNewswire/ -- PureHealth Holding PJSC ("PureHealth" or "the Group") (ADX Symbol: PUREHEALTH), the largest healthcare group in the Middle East, today announced its financial results for the six-month period ended 30 June 2026. The Group delivered a strong financial and operational performance during the first half of the year, primarily supported by continued momentum across its international Care (healthcare) platform and resilient growth in the Cover (insurance) vertical.

Group revenue increased 9% year-on-year to USD 4.0 billion, driven by continued expansion of PureHealth's international Care portfolio following the integration of Hellenic Healthcare Group (HHG) in Greece and Cyprus, alongside sustained growth in the Cover vertical in H1 2026. EBITDA increased 24% year-on-year to USD 782 million, reflecting the increasing contribution from higher-margin international operations and ongoing operational transformation across the Group in H1 2026. Net profit increased 20% year-on-year to USD 337 million in the same period.

H.E. Kamal Al Maazmi, Chairman of PureHealth, said: "PureHealth's performance in the first half of 2026 reflects the strength of our long-term strategy and the disciplined execution of our vision to build a globally diversified healthcare group with a resilient portfolio and a strong financial foundation. As our international operations continue to expand alongside our established leadership in the UAE, we remain focused on strengthening the resilience of our business, diversifying our earnings base, and reinforcing the foundations for sustainable long-term growth. We will continue to maintain disciplined capital allocation, directing investments towards opportunities that advance our strategic priorities and enhance our ability to create sustainable value for our shareholders and the communities we serve."

Shaista Asif, Group Chief Executive Officer of PureHealth, commented: "The first half of the year demonstrated the strength and resilience of our integrated platform model, delivering profitable growth across our business. Our international portfolio continued to scale, insurance maintained strong momentum, and patient activity across our UAE network grew in the second quarter. At the same time, we continued to invest in advanced clinical capabilities, digital front door of PURA, AI-enabled technologies and capacity expansion across our ecosystem. These investments are strengthening the quality of services we provide today while positioning PureHealth for its next phase of growth."

Financial & Operational Highlights Across the Care and Cover Verticals

International (Care): Revenue increased 56% year-on-year to USD 1.3 billion in H1 2026, primarily reflecting the consolidation of HHG alongside continued underlying growth across Circle Health. EBITDA increased 65% year-on-year to USD 300 million in H1 2026, with EBITDA margin expanding to 22.2%, highlighting the margin-accretive nature of the Group's international portfolio. Circle Health in the UK continued to deliver solid underlying performance, with revenue increasing 6.3% year-on-year, supported by a greater proportion of higher-acuity and more complex inpatient procedures. HHG maintained strong momentum across Greece and Cyprus, with patient volumes increasing 6% year-on-year, driven primarily by outpatient growth in H1 2026. International operations accounted for 33% of Group revenue during H1 2026, strengthening PureHealth's geographic diversification and earnings resilience.

UAE (Care): Revenue registered USD 1.6 billion in H1 2026. Patient activity strengthened through the second quarter, supported by heightened patient activity across the network. Outpatient volumes increased 7% year-on-year and inpatient volumes increased 10%, while bed occupancy across UAE hospitals increased to 75% in H1 2026. EBITDA increased 7% year-on-year to USD 332 million, reflecting improved underlying operational performance, stronger patient activity and continued cost discipline across the business in H1 2026.

Insurance (Cover): Revenue increased 10% year-on-year to USD 1.1 billion. Gross Written Premium increased 13% year-on-year to USD 1.5 billion, supported by strong renewals, disciplined underwriting, and continued new business growth in H1 2026. The number of insured members increased 4% year-on-year to 3.4 million, while Daman's Property & Casualty business continued to build momentum, generating approximately USD 22 million in Gross Written Premium during H1 2026 as all product lines gained market traction. In June, Daman was assigned an A1 Insurance Financial Strength Rating (IFSR) by Moody's Ratings with a stable outlook. The A1 rating, the highest IFSR assigned by Moody's to a UAE insurer, reinforces Daman's financial strength, market leadership, and resilient business model.

Key Strategic Updates

   -- PureHealth launched the Abu Dhabi Health Research Centre (ADHRC), an 
      integrated clinical research division that consolidates all research 
      activities across PureHealth's Abu Dhabi hospitals, primary care clinics, 
      and advanced laboratories. 
 
   -- PureHealth partnered with one of UAE's largest real estate developers 
      Aldar Properties, to integrate healthcare, preventive wellness, and 
      longevity-focused living into future communities across the UAE. 
 
   -- PureHealth launched the University of Nicosia (UNIC) campus in Athens, 
      advancing its integrated care, research, and education strategy in 
      Europe. 
 
   -- PureHealth marked the groundbreaking of the SEHA New Corniche Hospital 
      for Women and Newborns, a landmark 108,000-square-metre healthcare 
      development featuring 357 beds, with construction now underway. 
 
   -- PureHealth performed the GCC's first craniopagus twins separation 
      procedure in Abu Dhabi, showcasing its excellence in complex and 
      specialised care. 
 
   -- PureHealth launched SAKINA for Children, a dedicated mental health 
      network designed to deliver specialised services for children and 
      adolescents across the UAE. 
 
   -- PureHealth continued advancing AI-enabled transformation across the Group, 
      with HHG commencing the rollout of PureNet, PureHealth's in-house 
      developed healthcare cloud, to enhance clinical integration across its 
      international network. 
 
   -- Rafed expanded AI-powered sourcing capabilities enhancing its operational 
      KPIs, while PureCS accelerated enterprise-wide automation and AI adoption 
      across core business functions. 
 
   -- Circle Health expanded outpatient and diagnostic capacity across its 
      network while strengthening specialist capabilities through deployment of 
      a second 'Da Vinci 5' robotic surgical system, expansion of robotic 
      orthopaedics, and continued investment in complex surgery and diagnostic 
      infrastructure. 
 
   -- Circle completed the world's first AutoPlan-enabled total knee 
      arthroplasty using the VELYS$(TM)$ robotic system. The inaugural case was 
      at The Park Hospital and showcases Circle's leadership in complex 
      orthopaedics. 
 
   -- HHG expanded advanced diagnostic capabilities, hospital infrastructure 
      and specialised services, including new Pulmonary Nodule Centres, One-Day 
      Clinics, and internationally accredited IVF and medical training 
      capabilities. 
 
   -- Daman continued expanding its Property & Casualty platform, broadening 
      its multi-line insurance offering while maintaining underwriting 
      discipline and operational readiness for future growth. 
 
   -- SEHA and Sheikh Shakhbout Medical City (SSMC) expanded advanced 
      diagnostic services, specialised clinical programmes and high-acuity care, 
      including advanced oncology, cardiology, trauma and robotic surgery 
      capabilities. 
 
   -- SEHA became the first healthcare provider in the UAE to offer histotripsy 
      technology, an advanced non-invasive treatment for liver tumours at SEHA 
      Tawam Hospital. 

Outlook

Following a strong first half of 2026, PureHealth remains confident in its medium-term growth trajectory and is reaffirming its strategic and financial targets. The Group continues to benefit from an increasingly diversified earnings base, with its international healthcare platform, expanding insurance business, and resilient UAE operations providing multiple drivers of sustainable growth. Looking ahead, PureHealth expects continued momentum across its international portfolio as recent acquisitions mature, operational synergies deepen, and investments in specialised clinical capabilities continue to enhance returns. In the UAE, the Group expects underlying activity to remain healthy, supported by growing demand, expanded capacity, and an increasing focus on higher-acuity services. At the same time, Daman will continue scaling its Property & Casualty business while maintaining underwriting discipline and strengthening its multi-line insurance platform.

View original content to download multimedia:https://www.prnewswire.com/news-releases/purehealth-reports-net-profit-of-usd-337-million-in-h1-2026-302840011.html

SOURCE PureHealth

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10